Lewy Body Dementia Global Market Report 2025

Lewy body dementia (LBD) is a neurodegenerative disorder caused by abnormal protein deposits in the brain, affecting cognition, movement, and behavior. This leads to a gradual decline in both mental and physical abilities, with symptoms such as memory loss, hallucinations, tremors, and motor impairments. Proper management is crucial to address the cognitive and physical challenges associated with the condition.

Primary diagnosis of Lewy body dementia is conducted through clinical and biomarker-based methods. Clinical diagnosis involves assessing medical history, symptoms, and physical examinations to facilitate early detection and treatment. Management of the condition includes medications such as cholinesterase inhibitors, antipsychotics, and antidepressants. Various healthcare settings, including hospitals, specialty clinics, and long-term care facilities, play a crucial role in providing treatment and support.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The lewy body dementia market research report is one of a series of new reports from The Business Research Company that provides lewy body dementia market statistics, including the lewy body dementia industry global market size, regional shares, competitors with the lewy body dementia market share, detailed lewy body dementia market segments, market trends, and opportunities, and any further data you may need to thrive in the lewy body dementia industry. This lewy body dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lewy body dementia market size has grown strongly in recent years. It will grow from $1.12 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to aging population growth, increasing awareness of neurodegenerative diseases, rise in healthcare expenditures, improved diagnostic criteria, and regulatory approvals for dementia drugs.

The lewy body dementia market size is expected to see strong growth in the next few years. It will grow to $1.58 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing prevalence of dementia, growing investment in research and development, rising demand for early diagnosis, expanding telemedicine adoption, and focus on personalized medicine. Major trends in the forecast period include development of targeted therapies, expansion of clinical trials, advances in diagnostic techniques, technological advancements, and emphasis on novel therapeutics.

The forecast of 7.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. neurology clinics by increasing costs for specialized PET tracers and cognitive assessment tools sourced from Canada and the Netherlands, potentially delaying accurate dementia diagnoses and raising neurodegenerative disease care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of brain-related disorders is expected to drive the growth of the Lewy body dementia market. Brain-related disorders encompass a range of conditions that affect the brain's structure and function, leading to cognitive decline, memory loss, and behavioral changes. The rising occurrence of these disorders is attributed to factors such as aging, genetic predisposition, and environmental influences. As brain-related disorders become more common, the demand for improved treatments and early detection for Lewy body dementia is also rising. This increased demand accelerates research, funding, and innovation, leading to faster advancements in diagnosis and therapy for the condition. For instance, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the global population is affected by neurological conditions, with this burden projected to nearly double by 2050. Therefore, the rising prevalence of brain-related disorders is expected to contribute to the expansion of the Lewy body dementia market.

Leading companies in the Lewy body dementia market are prioritizing research investments to develop more effective treatments for neurodegenerative diseases. Research investment involves allocating financial resources, time, and effort to scientific and technological studies aimed at gaining new insights, developing innovative solutions, and enhancing existing treatments. Such investments support disease exploration and the development of new medications, ultimately improving patient outcomes. For example, in March 2023, the National Institute on Aging, a US-based government agency, awarded $21 million to fund drug development research for Lewy body dementia (LBD). Researchers at the University of Miami Miller School of Medicine have launched a Phase 2b study of neflamapimod following promising early results.

In March 2023, CND Life Sciences, a US-based developer of highly accurate skin-based tests for diagnosing dementia with Lewy bodies, partnered with Beth Israel Deaconess Medical Center (BIDMC) to enhance its diagnostic tool for neurodegenerative diseases. This collaboration aims to leverage advanced technology to improve the detection of misfolded alpha-synuclein proteins and explore additional protein markers linked to other neurodegenerative conditions. The goal is to facilitate more accurate diagnoses and enhance patient outcomes as new therapies become available. Beth Israel Deaconess Medical Center (BIDMC) is a US-based institution specializing in diagnosing and treating conditions such as Lewy body disease.

Major players in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer's Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., and EIP Pharma Inc.

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lewy body dementia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lewy body dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lewy body dementia market consists of revenues earned by entities by providing services such as cognitive and motor function therapies, pharmaceutical treatments, and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia market also includes sales of sleep aids, mood stabilizers, and anxiolytics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lewy Body Dementia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lewy body dementia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lewy body dementia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lewy body dementia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis: Clinical Diagnosis; Biomarker-Based Diagnosis
• 2) By Medication: Cholinesterase Inhibitors; Antipsychotics; Antidepressants; Other Medications
• 3) By End-User: Hospitals; Specialty Clinics; Long-Term Care Facilities; Other End-Users
• Subsegments:
• 1) By Clinical Diagnosis: Neuropsychological Testing; Neurological Examination; Medical History Review; Cognitive Function Assessment
• 2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers; Imaging Biomarkers (PET, MRI); Genetic Biomarkers; Blood-Based Biomarkers
• Companies Mentioned: Eli Lilly and Company; Mayo Foundation for Medical Education and Research; Eisai Co. Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Georgetown University Medical Center; Alzheimer's Society; BioArctic AB; Annovis Bio Inc.; Sun Pharma Advanced Research Company Limited; Voyager Therapeutics Inc.; Cognition Therapeutics; Athira Pharma; Allergan plc; Inhibikase Therapeutics; CuraSen Therapeutics Inc.; CervoMed Inc.; AC Immune SA; ProMIS Neurosciences Inc.; Aptinyx Inc.; EIP Pharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.